Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β.

Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, Messer J, Oroszlan K, Rauchenberger R, Richter WF, Rothe C, Urban M, Bardroff M, Winter M, Nordstedt C, Loetscher H.

J Alzheimers Dis. 2012;28(1):49-69. doi: 10.3233/JAD-2011-110977.

PMID:
21955818
2.

Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease.

Panza F, Solfrizzi V, Imbimbo BP, Giannini M, Santamato A, Seripa D, Logroscino G.

Expert Rev Neurother. 2014 Sep;14(9):973-86. doi: 10.1586/14737175.2014.945522. Epub 2014 Aug 1. Review.

PMID:
25081412
3.

Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies.

Geylis V, Steinitz M.

Autoimmun Rev. 2006 Jan;5(1):33-9. Epub 2005 Aug 1. Review.

PMID:
16338209
5.

Gantenerumab for the treatment of Alzheimer's disease.

Delrieu J, Ousset PJ, Vellas B.

Expert Opin Biol Ther. 2012 Aug;12(8):1077-86. doi: 10.1517/14712598.2012.688022. Epub 2012 May 15. Review.

PMID:
22583155
6.

Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward.

Panza F, Solfrizzi V, Imbimbo BP, Tortelli R, Santamato A, Logroscino G.

Expert Rev Clin Immunol. 2014 Mar;10(3):405-19. doi: 10.1586/1744666X.2014.883921. Epub 2014 Feb 4. Review.

PMID:
24490853
7.

Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?

Panza F, Solfrizzi V, Imbimbo BP, Logroscino G.

Expert Opin Biol Ther. 2014 Oct;14(10):1465-76. doi: 10.1517/14712598.2014.935332. Epub 2014 Jun 30. Review.

PMID:
24981190
8.

Profile of gantenerumab and its potential in the treatment of Alzheimer's disease.

Novakovic D, Feligioni M, Scaccianoce S, Caruso A, Piccinin S, Schepisi C, Errico F, Mercuri NB, Nicoletti F, Nisticò R.

Drug Des Devel Ther. 2013 Nov 13;7:1359-64. doi: 10.2147/DDDT.S53401. eCollection 2013. Review. Erratum in: Drug Des Devel Ther. 2014;8:569.

9.

Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?

Panza F, Logroscino G, Imbimbo BP, Solfrizzi V.

Curr Opin Psychiatry. 2014 Mar;27(2):128-37. doi: 10.1097/YCO.0000000000000041. Review.

PMID:
24445401
10.

How to get from here to there: macrophage recruitment in Alzheimer's disease.

Rezai-Zadeh K, Gate D, Gowing G, Town T.

Curr Alzheimer Res. 2011 Mar;8(2):156-63. Review.

11.

Antiretroviral medications disrupt microglial phagocytosis of β-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders.

Giunta B, Ehrhart J, Obregon DF, Lam L, Le L, Jin J, Fernandez F, Tan J, Shytle RD.

Mol Brain. 2011 Jun 7;4(1):23. doi: 10.1186/1756-6606-4-23. Review.

12.

The AbetaCs of Abeta-cleaving proteases.

Leissring MA.

J Biol Chem. 2008 Oct 31;283(44):29645-9. doi: 10.1074/jbc.R800022200. Epub 2008 Aug 22. Review.

13.

Human antibody production in transgenic animals.

Brüggemann M, Osborn MJ, Ma B, Hayre J, Avis S, Lundstrom B, Buelow R.

Arch Immunol Ther Exp (Warsz). 2015 Apr;63(2):101-8. doi: 10.1007/s00005-014-0322-x. Epub 2014 Dec 3. Review.

Items per page

Supplemental Content

Write to the Help Desk